Literature DB >> 26687020

Evaluation of the treatment of chronic chemotherapy-induced peripheral neuropathy using long-wave diathermy and interferential currents: a randomized controlled trial.

Katarina Lindblad1, Leif Bergkvist2, Ann-Christin Johansson3.   

Abstract

PURPOSE: The purpose was to investigate the effects of long-wave diathermy in combination with interferential currents (interferential therapy and long-wave diathermy at high power (ITH)) in comparison with long-wave diathermy at a power below the active treatment dose (long-wave diathermy at low power (LDL), control group) on sensory and motor symptoms in patients with chronic chemotherapy-induced peripheral neuropathy (CIPN) in the lower extremities.
METHODS: Sixty-seven patients with chronic CIPN were randomized to 12 weeks of either ITH or LDL. Follow-up assessments were performed after the treatment period and at 37 weeks after randomization. The primary outcome was pain (Numeric Rating Scale (NRS)), and the secondary outcomes were discomfort, nerve symptoms, subjective measurement of dizziness (Dizziness Handicap Inventory), and balance. Differences within and between groups were analyzed.
RESULTS: Pain intensity decreased significantly only in the LDL group directly after the treatment period from NRS median 25 to median 12.5 (P = 0.017). At the 37-week follow-up, no changes were detected, irrespective of group (NRS 13 vs. 20, P = 0.885). Discomfort decreased significantly in both groups at both 12 and 37 weeks after the baseline (P < 0.05). Balance disability showed significant declines in both groups at 12 and 37 weeks (P = 0.001/0.025 in the ITH group vs P = 0.001/<0.001 in the LDL group). Balance ability (tightened Romberg test) increased significantly at both 12 and 37 weeks in both groups (P = 0.004/<0.040 in the ITH group) but did not improve in the LDL group at any of the follow-up time points (P = 0.203 vs P = 0.383). The one-legged stance test was unchanged in the ITH group after 12 weeks but improved 37 weeks after baseline (P = 0.03). No significant changes were observed in the LDL group at any of the follow-up time points.
CONCLUSION: This study provides no support for the use of a combination of long-wave diathermy and ITH as a treatment option for patients with chronic CIPN. However, the chronic CIPN symptoms decreased with time irrespective of the treatment.

Entities:  

Keywords:  Cancer; Diathermy; Electrotherapy; Interferential current; Physical therapy

Mesh:

Year:  2015        PMID: 26687020     DOI: 10.1007/s00520-015-3060-7

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  25 in total

Review 1.  Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies.

Authors:  Sherry Wolf; Debra Barton; Lisa Kottschade; Axel Grothey; Charles Loprinzi
Journal:  Eur J Cancer       Date:  2008-06-18       Impact factor: 9.162

2.  Assessing quality of life in patients with cancer: a comparison of a visual-analogue and a categorical model.

Authors:  F Giorgi; R Cellerino; A Gramazio; D Tummarello; E T Menichetti; P Giordani; S Antognoli; F Carle; A Piga
Journal:  Am J Clin Oncol       Date:  1996-08       Impact factor: 2.339

Review 3.  Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): a systematic review.

Authors:  Janet M Schloss; Maree Colosimo; Caroline Airey; Paul P Masci; Anthony W Linnane; Luis Vitetta
Journal:  Clin Nutr       Date:  2013-04-13       Impact factor: 7.324

Review 4.  Management of chemotherapy-induced peripheral neuropathy.

Authors:  Mark Stillman; Juan P Cata
Journal:  Curr Pain Headache Rep       Date:  2006-08

5.  Chemotherapy-induced neuropathy.

Authors:  Guido Cavaletti; Paola Alberti; Barbara Frigeni; Marialuisa Piatti; Emanuela Susani
Journal:  Curr Treat Options Neurol       Date:  2011-04       Impact factor: 3.598

6.  Evaluation of acupuncture in the management of chemotherapy-induced peripheral neuropathy.

Authors:  Graeme K Donald; Irene Tobin; Jacqui Stringer
Journal:  Acupunct Med       Date:  2011-09       Impact factor: 2.267

7.  Quantified pain drawing in subacute low back pain. Validation in a nonselected outpatient industrial sample.

Authors:  C Ohlund; C Eek; S Palmbald; B Areskoug; A Nachemson
Journal:  Spine (Phila Pa 1976)       Date:  1996-05-01       Impact factor: 3.468

8.  Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).

Authors:  Deirdre R Pachman; Rui Qin; Drew K Seisler; Ellen M L Smith; Andreas S Beutler; Lauren E Ta; Jacqueline M Lafky; Nina D Wagner-Johnston; Kathryn J Ruddy; Shaker Dakhil; Nathan P Staff; Axel Grothey; Charles L Loprinzi
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

9.  Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3.

Authors:  Ravi D Rao; Patrick J Flynn; Jeff A Sloan; Gilbert Y Wong; Paul Novotny; David B Johnson; Howard M Gross; Samer I Renno; Mohammed Nashawaty; Charles L Loprinzi
Journal:  Cancer       Date:  2008-06-15       Impact factor: 6.860

10.  Pilot evaluation of Scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy.

Authors:  Deirdre R Pachman; Breanna L Weisbrod; Drew K Seisler; Debra L Barton; Kelliann C Fee-Schroeder; Thomas J Smith; Daniel H Lachance; Heshan Liu; Randy A Shelerud; Andrea L Cheville; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2014-09-24       Impact factor: 3.603

View more
  2 in total

Review 1.  Pharmacological and Nonpharmacological Management of Chemotherapy-Induced Peripheral Neuropathy: A Scoping Review of Randomized Controlled Trials.

Authors:  Katie Fitzgerald Jones; Stephen Wechsler; David Zulewski; Lisa Wood
Journal:  J Palliat Med       Date:  2022-02-04       Impact factor: 2.947

2.  Physiotherapy management of chemotherapy-induced peripheral neuropathy in Pretoria, South Africa.

Authors:  Esther A Niemand; Maria E Cochrane; Carina A Eksteen
Journal:  S Afr J Physiother       Date:  2020-10-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.